Basic Information


GTO ID GTC0310
Trial ID NCT02765243
Disease Neuroblastoma
Altered gene GD2
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment GD2 CAR-T cells
Generation4th
PhasePhase1
Recruitment statusSuspended
TitleAnti-GD2 4th Generation cells Targeting Refractory and/or Recurrent Neuroblastoma
Year2016
CountryChina
Company sponsorZhujiang Hospital
Other ID(s)2016-EKZX-001
Vector information
Vectorlentivirus
ConstructscFv-CD28-4-1BB-CD3ζ
Vector typeNHP/TYF lentivector system
Additional featureiCasp9

Clinical Result

Cohort 1
Administration route intravenous infusion
Dosage 0.13~34E6 cells/kg
Donor type Autologous
Pts 10
Age Child
Lymph depletion Yes
Outcome 4/10(PR); 6/10(SD). The median overall survival (OS) time was 25 months (95% CI, 0.00–59.43), and the median progression-free survival (PFS) time was 8 months (95% CI, 0.25–15.75)
References PMID: 34724115

Relationship Graph

Overview of Knowledge Graph